197 related articles for article (PubMed ID: 32451553)
1. Signalling by lysophosphatidate and its health implications.
Hemmings DG; Brindley DN
Essays Biochem; 2020 Sep; 64(3):547-563. PubMed ID: 32451553
[TBL] [Abstract][Full Text] [Related]
2. Role of the autotaxin-lysophosphatidate axis in the development of resistance to cancer therapy.
Tang X; Benesch MGK; Brindley DN
Biochim Biophys Acta Mol Cell Biol Lipids; 2020 Aug; 1865(8):158716. PubMed ID: 32305571
[TBL] [Abstract][Full Text] [Related]
3. Dexamethasone decreases the autotaxin-lysophosphatidate-inflammatory axis in adipose tissue: implications for the metabolic syndrome and breast cancer.
Meng G; Tang X; Yang Z; Zhao Y; Curtis JM; McMullen TPW; Brindley DN
FASEB J; 2019 Feb; 33(2):1899-1910. PubMed ID: 30192654
[TBL] [Abstract][Full Text] [Related]
4. Role of Adipose Tissue-Derived Autotaxin, Lysophosphatidate Signaling, and Inflammation in the Progression and Treatment of Breast Cancer.
Brindley DN; Tang X; Meng G; Benesch MGK
Int J Mol Sci; 2020 Aug; 21(16):. PubMed ID: 32824846
[TBL] [Abstract][Full Text] [Related]
5. Regulation of autotaxin expression and secretion by lysophosphatidate and sphingosine 1-phosphate.
Benesch MG; Zhao YY; Curtis JM; McMullen TP; Brindley DN
J Lipid Res; 2015 Jun; 56(6):1134-44. PubMed ID: 25896349
[TBL] [Abstract][Full Text] [Related]
6. Regulation of lysophosphatidate signaling by autotaxin and lipid phosphate phosphatases with respect to tumor progression, angiogenesis, metastasis and chemo-resistance.
Samadi N; Bekele R; Capatos D; Venkatraman G; Sariahmetoglu M; Brindley DN
Biochimie; 2011 Jan; 93(1):61-70. PubMed ID: 20709140
[TBL] [Abstract][Full Text] [Related]
7. Autotaxin-LPA-LPP3 Axis in Energy Metabolism and Metabolic Disease.
Jose A; Kienesberger PC
Int J Mol Sci; 2021 Sep; 22(17):. PubMed ID: 34502491
[TBL] [Abstract][Full Text] [Related]
8. Role of the autotaxin-lysophosphatidate axis in cancer resistance to chemotherapy and radiotherapy.
Brindley DN; Lin FT; Tigyi GJ
Biochim Biophys Acta; 2013 Jan; 1831(1):74-85. PubMed ID: 22954454
[TBL] [Abstract][Full Text] [Related]
9. Targeting the autotaxin - Lysophosphatidic acid receptor axis in cardiovascular diseases.
Zhao Y; Hasse S; Zhao C; Bourgoin SG
Biochem Pharmacol; 2019 Jun; 164():74-81. PubMed ID: 30928673
[TBL] [Abstract][Full Text] [Related]
10. The role and therapeutic potential of the autotaxin-lysophosphatidate signalling axis in breast cancer.
Teo K; Brunton VG
Biochem J; 2014 Oct; 463(1):157-65. PubMed ID: 25195735
[TBL] [Abstract][Full Text] [Related]
11. Autotaxin inhibition reduces cardiac inflammation and mitigates adverse cardiac remodeling after myocardial infarction.
Tripathi H; Al-Darraji A; Abo-Aly M; Peng H; Shokri E; Chelvarajan L; R Donahue R; Levitan BM; Gao E; Hernandez G; Morris AJ; Smyth SS; Abdel-Latif A
J Mol Cell Cardiol; 2020 Dec; 149():95-114. PubMed ID: 33017574
[TBL] [Abstract][Full Text] [Related]
12. Autotaxin and chronic inflammatory diseases.
Magkrioti C; Galaris A; Kanellopoulou P; Stylianaki EA; Kaffe E; Aidinis V
J Autoimmun; 2019 Nov; 104():102327. PubMed ID: 31471142
[TBL] [Abstract][Full Text] [Related]
13. The Autotaxin-Lysophosphatidic Acid Axis Promotes Lung Carcinogenesis.
Magkrioti C; Oikonomou N; Kaffe E; Mouratis MA; Xylourgidis N; Barbayianni I; Megadoukas P; Harokopos V; Valavanis C; Chun J; Kosma A; Stathopoulos GT; Bouros E; Bouros D; Syrigos K; Aidinis V
Cancer Res; 2018 Jul; 78(13):3634-3644. PubMed ID: 29724718
[TBL] [Abstract][Full Text] [Related]
14. Roles for lysophosphatidic acid signaling in vascular development and disease.
Smyth SS; Kraemer M; Yang L; Van Hoose P; Morris AJ
Biochim Biophys Acta Mol Cell Biol Lipids; 2020 Aug; 1865(8):158734. PubMed ID: 32376340
[TBL] [Abstract][Full Text] [Related]
15. Implications for breast cancer treatment from increased autotaxin production in adipose tissue after radiotherapy.
Meng G; Tang X; Yang Z; Benesch MGK; Marshall A; Murray D; Hemmings DG; Wuest F; McMullen TPW; Brindley DN
FASEB J; 2017 Sep; 31(9):4064-4077. PubMed ID: 28539367
[TBL] [Abstract][Full Text] [Related]
16. Recent advances in targeting the autotaxin-lysophosphatidate-lipid phosphate phosphatase axis in vivo.
Benesch MG; Tang X; Venkatraman G; Bekele RT; Brindley DN
J Biomed Res; 2016 Jul; 30(4):272-84. PubMed ID: 27533936
[TBL] [Abstract][Full Text] [Related]
17. Lipid phosphate phosphatase-1 regulates lysophosphatidate-induced fibroblast migration by controlling phospholipase D2-dependent phosphatidate generation.
Pilquil C; Dewald J; Cherney A; Gorshkova I; Tigyi G; English D; Natarajan V; Brindley DN
J Biol Chem; 2006 Dec; 281(50):38418-29. PubMed ID: 17057224
[TBL] [Abstract][Full Text] [Related]
18. Lipid phosphate phosphatase-1 dephosphorylates exogenous lysophosphatidate and thereby attenuates its effects on cell signalling.
Pilquil C; Singh I; Zhang QX; Ling ZC; Buri K; Stromberg LM; Dewald J; Brindley DN
Prostaglandins Other Lipid Mediat; 2001 Apr; 64(1-4):83-92. PubMed ID: 11324709
[TBL] [Abstract][Full Text] [Related]
19. Regulation of tumor cell - Microenvironment interaction by the autotaxin-lysophosphatidic acid receptor axis.
Tigyi GJ; Yue J; Norman DD; Szabo E; Balogh A; Balazs L; Zhao G; Lee SC
Adv Biol Regul; 2019 Jan; 71():183-193. PubMed ID: 30243984
[TBL] [Abstract][Full Text] [Related]
20. Chronic rhinosinusitis with nasal polyps and without nasal polyps is associated with increased expression of lysophosphatidic acid-related molecules.
Park SJ; Jun YJ; Lee KJ; Hwang SM; Kim TH; Lee SH; Lee SH
Am J Rhinol Allergy; 2014; 28(3):199-207. PubMed ID: 24980231
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
